BPA Biosante Pharmaceuticals

BOCA RATON, Fla., April 2 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, reiterated their Strong Buy recommendation on Antares Pharma (AMEX:AIS) and a 12-18 month price target of $4.00. Stephen M. Dunn, Director of Research, issued the report. The report describes Antares Pharma's drug and injector pipelines where Mr. Dunn states "Antares is severely undervalued compared to their partner Biosante (AMEX:BPA). In fact, Antares owns the majority of Biosante's pipeline while retaining 100% of all European rights." Other near-term events for Antares will be launch of their injector by Teva (NASDAQ:TEVA) in the U.S. and the initiation of a Phase III trial for Anturol in Overactive Bladder Syndrome, a $2 billion market. A copy of the report may be obtained by contacting Dawson James Securities at 561-391-5555. About Dawson James Securities: Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.dawsonjames.com/ Disclosures: Dawson James has acted as an investment banker for Antares Pharma and the Firm and/or its directors and employees may own securities in the companies and may increase or decrease holdings in the future. The analyst certifies that 1) all of the views expressed accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst; 3) the analyst responsible for preparing this research report receives compensation based upon various factors, including total revenues of Dawson James and its affiliates, a portion of which is generated by investment banking activities and 4) the analyst and/or members of their immediate family do not own stock in the companies mentioned. Contact: Dawson James Securities Stephen M. Dunn, 561-208-2905 Fax: 561-391-5757 Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 130645. DATASOURCE: Dawson James Securities CONTACT: Stephen M. Dunn of Dawson James Securities, +1-561-208-2905, Fax: +1-561-391-5757 Web site: http://www.dawsonjames.com/

Copyright